The approval includes the use of either tumor tissue or plasma and follows previous approvals with Genentech's Tarceva (erlotinib) and AstraZeneca's Tagrisso (osimertinib).
Two new studies have uncovered expression-defined T cell subsets that seem to coincide with better or worse outcomes in breast cancer or non-small cell lung cancer.
This data is helping the agency understand how precision oncology drugs and tests are prescribed outside of clinical trials and in the broader cancer community.
The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.
A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
